Anti-Integrin alpha 9 antibody [EPR9722]
- RabMAb
- Recombinant
- KO Validated
- What is this?
Be the first to review this product! Submit a review
|
(7 Publications)
Rabbit Recombinant Monoclonal Integrin alpha 9 antibody. Suitable for IHC-P, WB and reacts with Human, Mouse samples. Cited in 7 publications.
View Alternative Names
Integrin alpha-9, Integrin alpha-RLC, ITGA9
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Integrin alpha 9 antibody [EPR9722] (AB140599)
Immunohistochemical analysis of paraffin embedded Human lung tissue labelling Integrin alpha 9 with ab140599 antibody at a dilution of 1/100.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Integrin alpha 9 antibody [EPR9722] (AB140599)
Immunohistochemical analysis of paraffin embedded Human skin tissue labelling Integrin alpha 9 with ab140599 antibody at a dilution of 1/100.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
- WB
Lab
Western blot - Anti-Integrin alpha 9 antibody [EPR9722] (AB140599)
Western blot : Rabbit Monoclonal[EPR9722] to Integrin alpha 9 ab140599 staining at 1/1000 dilution, shown in green; Mouse anti alpha Tubulin (ab7291) loading control staining at 1/20,000 dilution, shown in magenta. A band was observed at 100 kDa in Wild-type A549 cell lysates with no signal observed at this size in ITGA9 knockout A549 cell line. To generate this image, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 100pc LICOR in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit 800CW & Goat anti-Mouse 680RD at 1/20,000 dilution.
All lanes:
Western blot - Anti-Integrin alpha 9 antibody [EPR9722] (ab140599) at 1/1000 dilution
Lane 1:
Wild-type A549 at 20 µg
Lane 2:
ITGA9 knockout A549 at 20 µg
Secondary
Lanes 1 - 2:
Goat anti-Rabbit 800CW at 1/20000 dilution
Lanes 1 - 2:
Goat anti-Mouse 680RD at 1/20000 dilution
Predicted band size: 114 kDa,140 kDa
Observed band size: 100 kDa,95 kDa
false
- WB
Unknown
Western blot - Anti-Integrin alpha 9 antibody [EPR9722] (AB140599)
All lanes:
Western blot - Anti-Integrin alpha 9 antibody [EPR9722] (ab140599) at 1/1000 dilution
Lane 1:
NIH3T3 cell lysate at 10 µg
Lane 2:
A673 cell lysate at 10 µg
Lane 3:
HepG2 cell lysate at 10 µg
Lane 4:
A549 cell lysate at 10 µg
Secondary
All lanes:
HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 114 kDa
Observed band size: 140 kDa
false
- WB
CiteAb
Western blot - Anti-Integrin alpha 9 antibody [EPR9722] (AB140599)
Western Blotting using Anti-Integrin alpha 9 antibody [EPR9722], ab140599. Publication image from Sargent, M. A. et al., 2019, Nat Commun, 30622267. Legend direct from paper.
Thbs3 reduces surface integrin levels and destabilizes the sarcolemma. a Representative Western blots of sarcolemma protein extracts from hearts of tTA control, Thbs3 DTG, and Thbs4 DTG mice, assayed for integrin proteins and β-dystroglycan. Laminin2α2 and Cacna1c serve as loading controls. Quantitation is shown in Supplementary Figure 3a-k. The red box shows integrin proteins specifically reduced on the sarcolemma by Thbs3. b Western blots for input of microsomal protein extracts before immunoprecipitation for Thbs3 and β1D integrin and Cacna1c from NRVMs infected with Adβgal or AdThbs3 (left panel). The microsomal fraction was then immunoprecipitated (IP) for β1 integrin and blotted for the indicated proteins (right panel). Mouse IgG was used as a control for the IP. c Regimen of Evans blue dye (EBD) and isoproterenol (Iso, 300 mg/kg) injection to measure membrane permeability in the hearts of mice. d Representative histological heart sections from 3 tTA control and 3 Thbs3 DTG mice, imaged for WGA (green fluorescence) and leakage of EBD into the cardiomyocytes by red fluorescence subjected to the experimental regimen shown in c. Scale bars are 1 mm. e Regimen of Evans blue dye (EBD) injection after TAC surgery to measure membrane permeability in adult mice. Mice were sacrificed (Sac) 24 h after EBD injection, 1 week after TAC surgery. f, g Representative cardiac histological images of tTA control and Thbs3 DTG hearts 1 week after TAC surgery stained with WGA (green) and intracellular leakage of EBD (red) according to the experimental scheme shown in e, while g shows quantitation of EBD positive cells in the hearts of these mice. Scale bars are 100 µm. *P < 0.05 versus tTA control sham; two-tailed students T-test. Data are represented as percentage EBD positive cells (≥3000 cells from ≥8 animals). Error bars are +/− standard error of the mean and number of mice used is shown in the graph as individual data points
false
Related conjugates and formulations (1)
-
Anti-Integrin alpha 9 antibody [EPR9722] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
Integrin alpha 9 influences cell migration proliferation and survival through its interactions with ECM proteins like tenascin-C and osteopontin. It does not function alone; it forms part of a complex that includes various signaling molecules and cytoskeletal proteins. These associations facilitate communication between the cell cytoskeleton and the ECM influencing processes like wound healing and inflammation.
Pathways
Integrin alpha 9 plays roles in pathways such as the integrin signaling pathway and the focal adhesion pathway. It interacts closely with molecules like focal adhesion kinase (FAK) and Paxillin which are critical within these pathways. These relationships allow integrin alpha 9 to modulate cellular responses such as spreading migration and cellular structural organization.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (7)
Recent publications for all applications. Explore the full list and refine your search
Journal of nanobiotechnology 23:134 PubMed39987112
2025
Applications
Unspecified application
Species
Unspecified reactive species
Cancer management and research 13:925-939 PubMed33564267
2021
Applications
Unspecified application
Species
Unspecified reactive species
International journal of molecular sciences 21: PubMed32397533
2020
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 10:76 PubMed30622267
2019
Applications
Unspecified application
Species
Unspecified reactive species
Journal of immunology research 2018:4602570 PubMed29951557
2018
Applications
Unspecified application
Species
Unspecified reactive species
Journal of immunology (Baltimore, Md. : 1950) 199:3427-3436 PubMed29038247
2017
Applications
Unspecified application
Species
Unspecified reactive species
Oncotarget 8:87848-87859 PubMed29152125
2017
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com